10-K: Tenon Medical Reports FY2024 Results, Highlights Growth Strategy and Financial Outlook

Tenon Medical's 10-K filing reveals a focus on commercial expansion, product development, and addressing financial challenges to sustain operations and achieve profitability in the SI-Joint fusion market.

Summary

• Tenon Medical, Inc., a medical device company specializing in SI-Joint fusion, filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company's primary product is The Catamaran SI Joint Fusion System, a less invasive approach to sacroiliac joint fusion.
• Tenon Medical is focused on three commercial opportunities: primary SI Joint procedures, revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct.
• The company estimates that over 30 million American adults have chronic lower back pain, with 15% to 30% associated with the SI-Joint.
• Tenon initiated its national commercial launch of The Catamaran System in October 2022.
• The company believes the potential market for surgical intervention of the SI-Joint to be 279,000 procedures annually in the U.S. alone, for a potential annual market of approximately $2.0 billion.
• Tenon is conducting post-market clinical studies to evaluate the clinical outcomes of patients treated with The Catamaran System.
• The company's revenue for 2024 was $3.277 million, compared to $2.928 million in 2023.
• Tenon reported a net loss of $13.673 million for 2024, compared to a net loss of $15.581 million in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $6.535 million.
• The company acknowledges substantial doubt about its ability to continue as a going concern without additional funding.
• Tenon plans to raise additional capital through public or private equity offerings, debt financings, and collaborations.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's revenue growth and a reduction in net loss, the company faces significant financial challenges, including a going concern warning and a material weakness in internal controls. The need for further capital raises adds to the uncertainty.

Positives

• Revenue increased by 12% in 2024 compared to 2023.
• Net loss decreased by approximately $1.9 million in 2024 compared to 2023.
• Gross profit increased by 38% in 2024 compared to 2023.
• The company has received FDA 510(k) clearance for The Catamaran System.
• Tenon is conducting post-market clinical trials to demonstrate the technology's benefits.
• The company has a strong intellectual property position with issued and pending patents.

Negatives

• The company has incurred net losses since its inception in 2012.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company identified a material weakness in internal controls over financial reporting.
• The company is dependent on a limited number of contract manufacturers.
• The company operates in a very competitive business environment.
• The company currently manufactures and sells products used in a single procedure.

Risks

• The company may be unable to achieve or sustain profitability.
• Hospitals, clinicians, and other healthcare providers may be unable to obtain coverage and reimbursement from third-party payors for procedures performed using the company's products.
• The company may not be able to convince physicians that The Catamaran System is an attractive alternative to competitors' products.
• The company operates in a very competitive business environment.
• The company is dependent on a limited number of contract manufacturers.
• The company may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.
• The company is increasingly dependent on information technology, and its systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
• The medical device industry is characterized by patent litigation, and the company could become subject to litigation that could be costly.
• The company's business could suffer if it loses the services of key members of its senior management, key advisors or personnel.
• Various factors outside the company's direct control may adversely affect manufacturing and distribution of its product.
• The company may seek to grow its business through acquisitions of or investments in new or complementary businesses, products or technologies, and the failure to manage acquisitions or investments, or the failure to integrate them with its existing business, could have a material adverse effect on the company.
• The company's ability to protect its intellectual property and proprietary technology is uncertain.
• The size and future growth in the market for the SI-Joint fixation market have not been established based on market reports and the company's estimates are based on its own review and analysis of public information and may be smaller than the company estimates, possibly materially.
• The company has a limited operating history and may face difficulties encountered by early-stage companies in new and rapidly evolving markets.
• The company's failure to adequately protect personal information in compliance with evolving legal requirements could harm its business.
• Geopolitical conditions, including trade disputes and direct or indirect acts of war or terrorism, could have an adverse effect on the company's operations and financial results.

Future Outlook

The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund its operations and growth.

Industry Context

The SI-Joint fusion market is competitive, with several major medical device companies and new entrants. Tenon believes that refined approaches and improved implant design will open the door to enhanced adoption and further penetration of this important market.

Comparison to Industry Standards

• The document mentions SI-bone, Inc., Globus Medical, Inc., Medtronic plc, XTant Medical Holdings, Inc., and RTI Surgical, Inc. as primary competitors.
• SI-bone, Inc. is estimated to perform approximately 16,000 SI-Joint fixations a year, representing the largest market share.
• All other competitive devices are estimated to represent approximately another 5,000 potential SI-Joint procedures.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a Consulting Agreement with Richard Ferrari, a founder of the Company and its Executive Chairman.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by cost-cutting measures if the company is unable to raise additional capital.
• Customers (clinicians and hospitals) may be impacted by the company's ability to supply products and support services.
• Suppliers and contract manufacturers are subject to the company's financial stability and ability to meet its obligations.

Next Steps

• The company plans to expand its commercial reach and product offerings.
• Tenon will continue to conduct post-market clinical studies to evaluate the clinical outcomes of patients treated with The Catamaran System.
• The company intends to address the material weakness in internal controls over financial reporting.
• Tenon plans to seek additional funding through public or private equity offerings, debt financings, and collaborations.

Key Dates

Keywords

SI-Joint Fusion, Catamaran System, Medical Device, Sacroiliac Joint, Tenon Medical, FDA Clearance, Lower Back Pain, Implants, Surgery, Healthcare